person · Reporting owner

MAHONEY DAVID L

Disclosed activity across 3 companies

Tapewire entity: 21365
SEC CIK: 0001224091

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CORCEPT THERAPEUTICS INCCORT · Entity 2620	Director	August 18, 2026	August 20, 2026
Gen Digital Inc.SYMC · Entity 2098	Director	May 14, 2019	May 17, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CORCEPT THERAPEUTICS INC

Report date August 18, 2026 · Filed August 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust	1,232,161	Reported balance After 2026-08-18 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-08-18 · Sale · Disposed 4,984 · Balance 1,232,161 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Common StockSEC Table I · non-derivative	IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust	1,140,994	Reported balance After 2026-08-18 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-08-18 · Sale · Disposed 91,167 · Balance 1,140,994 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Common StockSEC Table I · non-derivative	IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust	1,133,939	Reported balance After 2026-08-18 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-08-18 · Sale · Disposed 7,055 · Balance 1,133,939 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Common StockSEC Table I · non-derivative	IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust	1,133,539	Reported balance After 2026-08-18 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-08-18 · Sale · Disposed 400 · Balance 1,133,539 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Common StockSEC Table I · non-derivative	IndirectThe Black Dog Private Foundation	26,147	Reported balance Holding disclosure · report date 2026-08-18 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 26,147

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.

F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

Gen Digital Inc.

Report date May 14, 2019 · Filed May 17, 2019 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectWinnifred C Ellis & David L Mahoney TR UA 06/25/1998 David L Mahoney and Winnifred C Ellis Trust	16,959	Reported balance Holding disclosure · report date 2019-05-14 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance 16,959 F1: On May 15, 2019, the reporting person mistakenly reported the issuance of 2,568 shares pursuant to the 2000 Director Equity Incentive Plan, as amended. This issuance did not in fact occur.
Common StockSEC Table I · non-derivative	Direct	184,464	Reported balance Holding disclosure · report date 2019-05-14 · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · Balance 184,464

Filing footnotes · ownership attribution and instrument terms

F1: On May 15, 2019, the reporting person mistakenly reported the issuance of 2,568 shares pursuant to the 2000 Director Equity Incentive Plan, as amended. This issuance did not in fact occur.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Adamas Pharmaceuticals Inc

Report date November 24, 2021 · Filed November 24, 2021

Section 16 reporting ended · disclosed 2021-11-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-11-24 transaction · row 1 1 source row Row 1 · 2021-11-24 · Other · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F2: This amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
Common StockSEC Table I · non-derivative	IndirectDavid L. Mahoney & Winnifred C. Ellis 1998 Family Trust	Reported balance After 2021-11-24 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-11-24 · Other · Disposed 112,781 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2029-06-04	Direct	Reported balance After 2021-11-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: $3.30 plus two CVRs per share underlying the stock option. F4: The stock option is fully vested and exercisable. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.08 · Expires 2029-09-10	Direct	Reported balance After 2021-11-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-11-24 · Disposition to issuer · Disposed 40,000 · Balance 0 F8: $2.02 plus two CVRs per share underlying the stock option. F7: The Option shares shall vest as follows: One third of the shares shall vest on each of September 11, 2020, September 11, 2021 and September 11, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2030-06-02	Direct	Reported balance After 2021-11-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F9: $5.40 plus two CVRs per share underlying the stock option. F4: The stock option is fully vested and exercisable. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2031-06-01	Direct	Reported balance After 2021-11-24 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F10: $2.89 plus two CVRs per share underlying the stock option. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").

F2: This amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.

F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.

F4: The stock option is fully vested and exercisable.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.

F6: $3.30 plus two CVRs per share underlying the stock option.

F7: The Option shares shall vest as follows: One third of the shares shall vest on each of September 11, 2020, September 11, 2021 and September 11, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

F8: $2.02 plus two CVRs per share underlying the stock option.

F9: $5.40 plus two CVRs per share underlying the stock option.

F10: $2.89 plus two CVRs per share underlying the stock option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 18, 2026 Filed Aug 20, 2026 20:30 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	SaleCommon Stock	400	$119.64	$47,855.24	Disclosure SEC source: 0001193125-26-359255 · ownership.xml · nonDerivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,133,539 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
August 18, 2026 Filed Aug 20, 2026 20:30 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	SaleCommon Stock	7,055	$118.88	$838,710.39	Disclosure SEC source: 0001193125-26-359255 · ownership.xml · nonDerivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,133,939 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
August 18, 2026 Filed Aug 20, 2026 20:30 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	SaleCommon Stock	91,167	$118.24	$10,779,367.28	Disclosure SEC source: 0001193125-26-359255 · ownership.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,140,994 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
August 18, 2026 Filed Aug 20, 2026 20:30 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	SaleCommon Stock	4,984	$117.47	$585,478.45	Disclosure SEC source: 0001193125-26-359255 · ownership.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,232,161 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
June 17, 2026 Filed Jun 18, 2026 20:30 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	SaleCommon Stock	20,000	$84.53	$1,690,506.00	Disclosure SEC source: 0001193125-26-275963 · ownership.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Black Dog Private Foundation Disclosed balance after: 26,147 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.44 to $85.11. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
May 21, 2026 Filed May 26, 2026 21:31 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $59.69	$0.00	Disclosure SEC source: 0001193125-26-239691 · ownership.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-05-21 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. Read SEC document
March 13, 2026 Filed Mar 17, 2026 23:52 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $5.86	$0.00	Disclosure SEC source: 0001193125-26-111518 · ownership.xml · derivative · entry 6 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2026-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document
March 13, 2026 Filed Mar 17, 2026 23:52 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	OtherCommon Stock	24,531	$0.00	$0.00	Disclosure SEC source: 0001193125-26-111518 · ownership.xml · nonDerivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,237,145 F2 · kind: Transfer of shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust. Read SEC document
March 13, 2026 Filed Mar 17, 2026 23:52 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GiftCommon Stock	24,531	$0.00	$0.00	Disclosure SEC source: 0001193125-26-111518 · ownership.xml · nonDerivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · kind: Transfer of shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust. Read SEC document
March 13, 2026 Filed Mar 17, 2026 23:52 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Tax withholdingCommon Stock	5,469	$32.15	$175,828.35	Disclosure SEC source: 0001193125-26-111518 · ownership.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,531 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options. Read SEC document
March 13, 2026 Filed Mar 17, 2026 23:52 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionCommon Stock	30,000	$5.86	$175,800.00	Disclosure SEC source: 0001193125-26-111518 · ownership.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 10, 2025 Filed Jun 13, 2025 00:39 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GrantStock option (right to buy) · Derivative	15,000	$0.00 Strike: $72.27	$0.00	Disclosure SEC source: 0000950170-25-085750 · ownership.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. Read SEC document
May 16, 2025 Filed May 20, 2025 23:13 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionStock option (right to buy) · Derivative	30,000	$0.00 Strike: $6.55	$0.00	Disclosure SEC source: 0000950170-25-075470 · ownership.xml · derivative · entry 7 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document
May 16, 2025 Filed May 20, 2025 23:13 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	SaleCommon Stock	3,523	$74.65	$263,000.76	Disclosure SEC source: 0000950170-25-075470 · ownership.xml · nonDerivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.54 to $74.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document
May 16, 2025 Filed May 20, 2025 23:13 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	SaleCommon Stock	23,829	$74.17	$1,767,451.74	Disclosure SEC source: 0000950170-25-075470 · ownership.xml · nonDerivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,523 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.54 to $74.525 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document
May 16, 2025 Filed May 20, 2025 23:13 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Tax withholdingCommon Stock	2,648	$74.21	$196,508.08	Disclosure SEC source: 0000950170-25-075470 · ownership.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,352 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price liability arising from a net (cashless) exercise of stock options that occurred on May 16, 2025. The options subject to the net exercise were to expire on June 18, 2025. Read SEC document
May 16, 2025 Filed May 20, 2025 23:13 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionCommon Stock	30,000	$6.55	$196,500.00	Disclosure SEC source: 0000950170-25-075470 · ownership.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 17, 2024 Filed May 21, 2024 22:28 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GrantStock option (right to buy) · Derivative	30,000	$0.00 Strike: $28.09	$0.00	Disclosure SEC source: 0000950170-24-063162 · ownership.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-16 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 17, 2024 over a one-year period. Read SEC document
April 10, 2024 Filed Apr 12, 2024 23:00 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionStock option (right to buy) · Derivative	30,000	$0.00 Strike: $1.74	$0.00	Disclosure SEC source: 0000950170-24-044185 · ownership.xml · derivative · entry 6 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2024-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document
April 10, 2024 Filed Apr 12, 2024 23:00 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	OtherCommon Stock	27,806	$0.00	$0.00	Disclosure SEC source: 0000950170-24-044185 · ownership.xml · nonDerivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,212,614 F2 · kind: Transfer of shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust. F3 · balance_after: The Form 4 previously filed inadvertently overstated the number of shares held by 15,000. The number in Column 5 reflects the corrected amount. Read SEC document
April 10, 2024 Filed Apr 12, 2024 23:00 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	OtherCommon Stock	27,806	$0.00	$0.00	Disclosure SEC source: 0000950170-24-044185 · ownership.xml · nonDerivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,806 F2 · kind: Transfer of shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust. Read SEC document
April 10, 2024 Filed Apr 12, 2024 23:00 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Tax withholdingCommon Stock	2,194	$23.80	$52,217.20	Disclosure SEC source: 0000950170-24-044185 · ownership.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,806 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on April 10, 2024. The options subject to the net exercise were to expire on May 8, 2024. Read SEC document
April 10, 2024 Filed Apr 12, 2024 23:00 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionCommon Stock	30,000	$1.74	$52,200.00	Disclosure SEC source: 0000950170-24-044185 · ownership.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 29, 2023 Filed Aug 31, 2023 22:03 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GiftCommon Stock	34,850	$0.00	$0.00	Disclosure SEC source: 0000950170-23-045848 · ownership.xml · nonDerivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Black Dog Private Foundation Disclosed balance after: 46,147 Read SEC document
August 29, 2023 Filed Aug 31, 2023 22:03 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GiftCommon Stock	34,850	$0.00	$0.00	Disclosure SEC source: 0000950170-23-045848 · ownership.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,169,808 Read SEC document
August 29, 2023 Filed Aug 31, 2023 22:03 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GiftCommon Stock	17,420	$0.00	$0.00	Disclosure SEC source: 0000950170-23-045848 · ownership.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,204,658 Read SEC document
August 14, 2023 Filed Aug 16, 2023 20:53 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	SaleCommon Stock	15,000	$30.95	$464,200.50	Disclosure SEC source: 0000950170-23-043043 · ownership.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,222,078 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $30.83 to $31.14. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
August 14, 2023 Filed Aug 16, 2023 20:53 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	SaleCommon Stock	10,000	$30.95	$309,467.00	Disclosure SEC source: 0000950170-23-043043 · ownership.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Plan reported Ownership: Indirect · The Black Dog Private Foundation Disclosed balance after: 11,297 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $30.83 to $31.14. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
May 19, 2023 Filed May 23, 2023 21:00 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GrantStock option (right to buy) · Derivative	30,000	$0.00 Strike: $24.10	$0.00	Disclosure SEC source: 0000899243-23-013734 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 19, 2023 over a one-year period. Read SEC document
May 08, 2023 Filed May 9, 2023 20:45 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionStock option (right to buy) · Derivative	30,000	$0.00 Strike: $1.74	$0.00	Disclosure SEC source: 0000899243-23-012472 · doc4.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2023-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document
May 08, 2023 Filed May 9, 2023 20:45 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Tax withholdingCommon Stock	2,197	$23.76	$52,200.72	Disclosure SEC source: 0000899243-23-012472 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,237,078 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on May 8, 2023. The options subject to the net exercise were to expire on May 17, 2023. F2 · balance_after: Fully exercisable. Read SEC document
May 08, 2023 Filed May 9, 2023 20:45 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionCommon Stock	30,000	$1.74	$52,200.00	Disclosure SEC source: 0000899243-23-012472 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,239,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Fully exercisable. Read SEC document
December 16, 2022 Filed Feb 15, 2023 00:30 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GiftCommon Stock	21,297	$0.00	$0.00	Disclosure SEC source: 0000899243-23-005067 · doc5.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,209,275 F1 · balance_after: This total includes 24,214 shares disclosed as being directly owned by the Reporting Person in a Form 4 filed on May 31, 2022. Read SEC document
December 13, 2022 Filed Feb 15, 2023 00:30 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GiftCommon Stock	26,030	$0.00	$0.00	Disclosure SEC source: 0000899243-23-005067 · doc5.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,230,572 Read SEC document
May 31, 2022 Filed Jun 2, 2022 21:00 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GrantStock option (right to buy) · Derivative	20,000	$0.00 Strike: $20.84	$0.00	Disclosure SEC source: 0000899243-22-020699 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-30 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 31, 2022 over a one-year period. Read SEC document
May 27, 2022 Filed May 31, 2022 21:11 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $4.05	$0.00	Disclosure SEC source: 0000899243-22-020211 · doc4.xml · derivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document
May 27, 2022 Filed May 31, 2022 21:11 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Tax withholdingCommon Stock	5,786	$21.00	$121,506.00	Disclosure SEC source: 0000899243-22-020211 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,214 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on May 27, 2022. The options subject to the net exercise were to expire on June 12, 2022. Read SEC document
May 27, 2022 Filed May 31, 2022 21:11 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionCommon Stock	30,000	$4.05	$121,500.00	Disclosure SEC source: 0000899243-22-020211 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 24, 2021 Filed Nov 24, 2021 21:11 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $5.21	Not disclosed	Disclosure SEC source: 0001328143-21-000094 · wf-form4_163778824532046.xml · derivative · entry 6 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2031-06-01 F10 · price: $2.89 plus two CVRs per share underlying the stock option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document
November 24, 2021 Filed Nov 24, 2021 21:11 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $2.70	Not disclosed	Disclosure SEC source: 0001328143-21-000094 · wf-form4_163778824532046.xml · derivative · entry 5 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2030-06-02 F9 · price: $5.40 plus two CVRs per share underlying the stock option. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document
November 24, 2021 Filed Nov 24, 2021 21:11 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	Disposition to issuerStock Option (Right to Buy) · Derivative	40,000	Not disclosed Strike: $6.08	Not disclosed	Disclosure SEC source: 0001328143-21-000094 · wf-form4_163778824532046.xml · derivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2029-09-10 F8 · price: $2.02 plus two CVRs per share underlying the stock option. F7 · derivative.exercise_date: The Option shares shall vest as follows: One third of the shares shall vest on each of September 11, 2020, September 11, 2021 and September 11, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document
November 24, 2021 Filed Nov 24, 2021 21:11 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $4.80	Not disclosed	Disclosure SEC source: 0001328143-21-000094 · wf-form4_163778824532046.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-06-04 F6 · price: $3.30 plus two CVRs per share underlying the stock option. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document
November 24, 2021 Filed Nov 24, 2021 21:11 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	OtherCommon Stock	112,781	Not disclosed	Not disclosed	Disclosure SEC source: 0001328143-21-000094 · wf-form4_163778824532046.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David L. Mahoney & Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F3 · price: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. Read SEC document
November 24, 2021 Filed Nov 24, 2021 21:11 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	OtherCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001328143-21-000094 · wf-form4_163778824532046.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F2 · shares: This amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F3 · price: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:15 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $5.21	$0.00	Disclosure SEC source: 0001328143-21-000059 · wf-form4_162283772332268.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-01 F2 · derivative.exercise_date: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:15 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001328143-21-000059 · wf-form4_162283772332268.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,153 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document
May 26, 2021 Filed May 28, 2021 21:16 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $21.45	$0.00	Disclosure SEC source: 0000899243-21-021146 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 26, 2021 over a one-year period. Read SEC document
May 11, 2021 Filed May 13, 2021 21:40 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $4.42	$0.00	Disclosure SEC source: 0000899243-21-019425 · doc4.xml · derivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document
May 11, 2021 Filed May 13, 2021 21:40 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Tax withholdingCommon Stock	6,484	$20.45	$132,597.80	Disclosure SEC source: 0000899243-21-019425 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on May 11, 2021. The options subject to the net exercise were to expire on May 19, 2021. Read SEC document
May 11, 2021 Filed May 13, 2021 21:40 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	Exercise / conversionCommon Stock	30,000	$4.42	$132,600.00	Disclosure SEC source: 0000899243-21-019425 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.